Eintrag weiter verarbeiten
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , |
| In: | Clinical Cancer Research, 11, 2005, 12, S. 4393-4399 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Ma, Yan Lespagnard, Laurence Durbecq, Virginie Paesmans, Marianne Desmedt, Christine Gomez-Galdon, Maria Veys, Isabelle Cardoso, Fatima Sotiriou, Christos Di Leo, Angelo Piccart, Martine J. Larsimont, Denis Ma, Yan Lespagnard, Laurence Durbecq, Virginie Paesmans, Marianne Desmedt, Christine Gomez-Galdon, Maria Veys, Isabelle Cardoso, Fatima Sotiriou, Christos Di Leo, Angelo Piccart, Martine J. Larsimont, Denis |
|---|---|
| author |
Ma, Yan Lespagnard, Laurence Durbecq, Virginie Paesmans, Marianne Desmedt, Christine Gomez-Galdon, Maria Veys, Isabelle Cardoso, Fatima Sotiriou, Christos Di Leo, Angelo Piccart, Martine J. Larsimont, Denis |
| spellingShingle |
Ma, Yan Lespagnard, Laurence Durbecq, Virginie Paesmans, Marianne Desmedt, Christine Gomez-Galdon, Maria Veys, Isabelle Cardoso, Fatima Sotiriou, Christos Di Leo, Angelo Piccart, Martine J. Larsimont, Denis Clinical Cancer Research Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice Cancer Research Oncology |
| author_sort |
ma, yan |
| spelling |
Ma, Yan Lespagnard, Laurence Durbecq, Virginie Paesmans, Marianne Desmedt, Christine Gomez-Galdon, Maria Veys, Isabelle Cardoso, Fatima Sotiriou, Christos Di Leo, Angelo Piccart, Martine J. Larsimont, Denis 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-04-2256 <jats:title>Abstract</jats:title> <jats:p>Purpose: To assess the effect of chromosome 17 copy number on HER-2/neu status determination in breast cancers.</jats:p> <jats:p>Experimental Design: HER-2/neu gene copy and chromosome 17 centromere numbers were evaluated on 893 breast carcinomas using double color fluorescence in situ hybridization (FISH). The net and chromosome 17 corrected (ratio) HER-2/neu copy numbers were compared and related to immunohistochemistry done according to the Food and Drug Administration (FDA)–approved scoring system (0, 1+, 2+, and 3+) as a first screening step in 584 cases.</jats:p> <jats:p>Results: When a ratio ≥2 was considered as criterion for FISH positivity, 49.3% (440 of 893) of cases showed amplification versus 56.2% (502 of 893) by using a net HER-2/neu gene copy number &gt;4 as a alternative criterion; 14.8% (67 of 453) of cases having a ratio &lt;2 had a net HER-2/neu gene copy number &gt;4 and 1.1% (5 of 440) with a ratio ≥2 had a net HER-2/neu gene copy number &lt;4. Among discordant cases, 88.8% (64 of 72) were polysomic (&gt;2.25 chromosomes 17/cell) and among polysomic cases, 12.8% (40 of 312) of the low polysomic (2.26-3.75 chromosomes 17/cell) and 36.9% (24 of 65) of the highly polysomic (&gt;3.75 chromosomes 17/cell) cases showed discordance. In cases with a ratio &lt;2, polysomy 17 incidences were 85.7% (6 of 7) in IHC 3+, 42.4% (79 of 186) in IHC 2+, 33.3% (15 of 45) in IHC 1+, and 29.1% (16 of 55) in IHC 0.</jats:p> <jats:p>Conclusion: A net increase in HER-2/neu gene copy number consecutive to polysomy 17 in the absence of specific gene amplification might lead to a strong protein overexpression in a small subset of breast carcinomas. HER-2/neu status determination by FISH is dependent on the criterion considered for positivity in clinical practice.</jats:p> Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-04-2256 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA0LTIyNTY |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA0LTIyNTY |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2005 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2005 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
ma2005polysomy17inher2neustatuselaborationinbreastcancereffectondailypractice |
| publishDateSort |
2005 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_unstemmed |
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_full |
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_fullStr |
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_full_unstemmed |
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_short |
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_sort |
polysomy 17 in her-2/neu status elaboration in breast cancer: effect on daily practice |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-04-2256 |
| publishDate |
2005 |
| physical |
4393-4399 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Purpose: To assess the effect of chromosome 17 copy number on HER-2/neu status determination in breast cancers.</jats:p>
<jats:p>Experimental Design: HER-2/neu gene copy and chromosome 17 centromere numbers were evaluated on 893 breast carcinomas using double color fluorescence in situ hybridization (FISH). The net and chromosome 17 corrected (ratio) HER-2/neu copy numbers were compared and related to immunohistochemistry done according to the Food and Drug Administration (FDA)–approved scoring system (0, 1+, 2+, and 3+) as a first screening step in 584 cases.</jats:p>
<jats:p>Results: When a ratio ≥2 was considered as criterion for FISH positivity, 49.3% (440 of 893) of cases showed amplification versus 56.2% (502 of 893) by using a net HER-2/neu gene copy number &gt;4 as a alternative criterion; 14.8% (67 of 453) of cases having a ratio &lt;2 had a net HER-2/neu gene copy number &gt;4 and 1.1% (5 of 440) with a ratio ≥2 had a net HER-2/neu gene copy number &lt;4. Among discordant cases, 88.8% (64 of 72) were polysomic (&gt;2.25 chromosomes 17/cell) and among polysomic cases, 12.8% (40 of 312) of the low polysomic (2.26-3.75 chromosomes 17/cell) and 36.9% (24 of 65) of the highly polysomic (&gt;3.75 chromosomes 17/cell) cases showed discordance. In cases with a ratio &lt;2, polysomy 17 incidences were 85.7% (6 of 7) in IHC 3+, 42.4% (79 of 186) in IHC 2+, 33.3% (15 of 45) in IHC 1+, and 29.1% (16 of 55) in IHC 0.</jats:p>
<jats:p>Conclusion: A net increase in HER-2/neu gene copy number consecutive to polysomy 17 in the absence of specific gene amplification might lead to a strong protein overexpression in a small subset of breast carcinomas. HER-2/neu status determination by FISH is dependent on the criterion considered for positivity in clinical practice.</jats:p> |
| container_issue |
12 |
| container_start_page |
4393 |
| container_title |
Clinical Cancer Research |
| container_volume |
11 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792345811444563970 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:29:26.452Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Polysomy+17+in+HER-2%2Fneu+Status+Elaboration+in+Breast+Cancer%3A+Effect+on+Daily+Practice&rft.date=2005-06-15&genre=article&issn=1557-3265&volume=11&issue=12&spage=4393&epage=4399&pages=4393-4399&jtitle=Clinical+Cancer+Research&atitle=Polysomy+17+in+HER-2%2Fneu+Status+Elaboration+in+Breast+Cancer%3A+Effect+on+Daily+Practice&aulast=Larsimont&aufirst=Denis&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-04-2256&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792345811444563970 |
| author | Ma, Yan, Lespagnard, Laurence, Durbecq, Virginie, Paesmans, Marianne, Desmedt, Christine, Gomez-Galdon, Maria, Veys, Isabelle, Cardoso, Fatima, Sotiriou, Christos, Di Leo, Angelo, Piccart, Martine J., Larsimont, Denis |
| author_facet | Ma, Yan, Lespagnard, Laurence, Durbecq, Virginie, Paesmans, Marianne, Desmedt, Christine, Gomez-Galdon, Maria, Veys, Isabelle, Cardoso, Fatima, Sotiriou, Christos, Di Leo, Angelo, Piccart, Martine J., Larsimont, Denis, Ma, Yan, Lespagnard, Laurence, Durbecq, Virginie, Paesmans, Marianne, Desmedt, Christine, Gomez-Galdon, Maria, Veys, Isabelle, Cardoso, Fatima, Sotiriou, Christos, Di Leo, Angelo, Piccart, Martine J., Larsimont, Denis |
| author_sort | ma, yan |
| container_issue | 12 |
| container_start_page | 4393 |
| container_title | Clinical Cancer Research |
| container_volume | 11 |
| description | <jats:title>Abstract</jats:title> <jats:p>Purpose: To assess the effect of chromosome 17 copy number on HER-2/neu status determination in breast cancers.</jats:p> <jats:p>Experimental Design: HER-2/neu gene copy and chromosome 17 centromere numbers were evaluated on 893 breast carcinomas using double color fluorescence in situ hybridization (FISH). The net and chromosome 17 corrected (ratio) HER-2/neu copy numbers were compared and related to immunohistochemistry done according to the Food and Drug Administration (FDA)–approved scoring system (0, 1+, 2+, and 3+) as a first screening step in 584 cases.</jats:p> <jats:p>Results: When a ratio ≥2 was considered as criterion for FISH positivity, 49.3% (440 of 893) of cases showed amplification versus 56.2% (502 of 893) by using a net HER-2/neu gene copy number &gt;4 as a alternative criterion; 14.8% (67 of 453) of cases having a ratio &lt;2 had a net HER-2/neu gene copy number &gt;4 and 1.1% (5 of 440) with a ratio ≥2 had a net HER-2/neu gene copy number &lt;4. Among discordant cases, 88.8% (64 of 72) were polysomic (&gt;2.25 chromosomes 17/cell) and among polysomic cases, 12.8% (40 of 312) of the low polysomic (2.26-3.75 chromosomes 17/cell) and 36.9% (24 of 65) of the highly polysomic (&gt;3.75 chromosomes 17/cell) cases showed discordance. In cases with a ratio &lt;2, polysomy 17 incidences were 85.7% (6 of 7) in IHC 3+, 42.4% (79 of 186) in IHC 2+, 33.3% (15 of 45) in IHC 1+, and 29.1% (16 of 55) in IHC 0.</jats:p> <jats:p>Conclusion: A net increase in HER-2/neu gene copy number consecutive to polysomy 17 in the absence of specific gene amplification might lead to a strong protein overexpression in a small subset of breast carcinomas. HER-2/neu status determination by FISH is dependent on the criterion considered for positivity in clinical practice.</jats:p> |
| doi_str_mv | 10.1158/1078-0432.ccr-04-2256 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA0LTIyNTY |
| imprint | American Association for Cancer Research (AACR), 2005 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2005 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T17:29:26.452Z |
| match_str | ma2005polysomy17inher2neustatuselaborationinbreastcancereffectondailypractice |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 4393-4399 |
| publishDate | 2005 |
| publishDateSort | 2005 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Ma, Yan Lespagnard, Laurence Durbecq, Virginie Paesmans, Marianne Desmedt, Christine Gomez-Galdon, Maria Veys, Isabelle Cardoso, Fatima Sotiriou, Christos Di Leo, Angelo Piccart, Martine J. Larsimont, Denis 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-04-2256 <jats:title>Abstract</jats:title> <jats:p>Purpose: To assess the effect of chromosome 17 copy number on HER-2/neu status determination in breast cancers.</jats:p> <jats:p>Experimental Design: HER-2/neu gene copy and chromosome 17 centromere numbers were evaluated on 893 breast carcinomas using double color fluorescence in situ hybridization (FISH). The net and chromosome 17 corrected (ratio) HER-2/neu copy numbers were compared and related to immunohistochemistry done according to the Food and Drug Administration (FDA)–approved scoring system (0, 1+, 2+, and 3+) as a first screening step in 584 cases.</jats:p> <jats:p>Results: When a ratio ≥2 was considered as criterion for FISH positivity, 49.3% (440 of 893) of cases showed amplification versus 56.2% (502 of 893) by using a net HER-2/neu gene copy number &gt;4 as a alternative criterion; 14.8% (67 of 453) of cases having a ratio &lt;2 had a net HER-2/neu gene copy number &gt;4 and 1.1% (5 of 440) with a ratio ≥2 had a net HER-2/neu gene copy number &lt;4. Among discordant cases, 88.8% (64 of 72) were polysomic (&gt;2.25 chromosomes 17/cell) and among polysomic cases, 12.8% (40 of 312) of the low polysomic (2.26-3.75 chromosomes 17/cell) and 36.9% (24 of 65) of the highly polysomic (&gt;3.75 chromosomes 17/cell) cases showed discordance. In cases with a ratio &lt;2, polysomy 17 incidences were 85.7% (6 of 7) in IHC 3+, 42.4% (79 of 186) in IHC 2+, 33.3% (15 of 45) in IHC 1+, and 29.1% (16 of 55) in IHC 0.</jats:p> <jats:p>Conclusion: A net increase in HER-2/neu gene copy number consecutive to polysomy 17 in the absence of specific gene amplification might lead to a strong protein overexpression in a small subset of breast carcinomas. HER-2/neu status determination by FISH is dependent on the criterion considered for positivity in clinical practice.</jats:p> Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice Clinical Cancer Research |
| spellingShingle | Ma, Yan, Lespagnard, Laurence, Durbecq, Virginie, Paesmans, Marianne, Desmedt, Christine, Gomez-Galdon, Maria, Veys, Isabelle, Cardoso, Fatima, Sotiriou, Christos, Di Leo, Angelo, Piccart, Martine J., Larsimont, Denis, Clinical Cancer Research, Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice, Cancer Research, Oncology |
| title | Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_full | Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_fullStr | Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_full_unstemmed | Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_short | Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| title_sort | polysomy 17 in her-2/neu status elaboration in breast cancer: effect on daily practice |
| title_unstemmed | Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-04-2256 |